Latest Breaking News On - புவியியல் அட்ரோஃபீ - Page 1 : comparemela.com

Confirm -EyeGate signs non-binding letter of intent to acquire Bayon Therapeutics, a private ophthalmic pharmaceutical company developing a novel, vision restoring small molecule platform- WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) EyeGate Pharmaceuticals, Inc. ( EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system, today announced that Brian M Strem, Ph.D., Co-Founder, Director and former Chief Executive Officer of Okogen, Inc as well as Co-Founder and Managing Director of Bayon Therapeutics, was appointed as permanent President, Chief Executive Officer and board member, effective immediately. He brings strategic expertise, scientific acumen and drug development experience in ophthalmology, otology and regenerative medicine to his new role.

Corey davisBrianm stremFranz obermayrCytori therapeuticsCornell universityOkogen incGlobal business developmentGlobal business development at shire pharmaceuticalsEyegate pharmaceuticals incClinical developmentBusiness developmentGate pharmaceuticalsChief executive officerManaging directorBayon therapeuticsStephen from